GlassScriptPhysician profile
Lyle Kirk Lorimer
NPI 1407945348
$759.38
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2022: $120 · 2023: $370 · 2024: $30.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $221 · Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $220.94 |
| Food and Beverage | $179.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $370.48 | 2023 | |
| Stryker Corporation | $100.00 | 2019 | |
| Heron Therapeutics, INC. | $53.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $37.26 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $34.45 | 2022 | |
| Nevro Corp. | $30.49 | 2022 | |
| Invictus Surgical Incorporated | $30.16 | 2024 | |
| Bioventus LLC | $28.33 | 2019 | |
| Pacira Therapeutics, INC. | $25.55 | 2019 | |
| Horizon Therapeutics Plc | $20.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.45 | 2022 | |
| Ferring Pharmaceuticals INC. | $11.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Lorimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.